Kaurenoic acid

Name: Kaurenoic acid
Brand: MedChemExpress
SKU: HY-N1469
Rating: 4.5 (1 reviews)

Cat. No.: HY-N1469 Purity: 99.56%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Kaurenoic acid is a diterpene derived from Sphagneticola trilobata. Kaurenoic acid has antibacterial, anti-inflammatory, anticonvulsant, analgesic, and aortic vasodilating effects.

For research use only. We do not sell to patients.

Kaurenoic acid Chemical Structure

CAS No. : 6730-83-2

Size	Price	Stock	Quantity
5 mg	USD 75	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 120	In-stock	Estimated Time of Arrival: December 31
20 mg	USD 190	In-stock	Estimated Time of Arrival: December 31
50 mg		Get quote
100 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Kaurenoic acid:

Kaurenoic acid (Standard) Get quote

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Kaurenoic acid is a diterpene derived from Sphagneticola trilobata. Kaurenoic acid has antibacterial, anti-inflammatory, anticonvulsant, analgesic, and aortic vasodilating effects^[1]^[2]^[3]^[4].

Cellular Effect

Cell Line	Type	Value	Description	References
A498	ED₅₀	47.97 μg/mL Compound: 2	Cytotoxicity against human A498 cells after 7 days by MTT assay Cytotoxicity against human A498 cells after 7 days by MTT assay	[PMID: 8882434]
A549	ED₅₀	13.59 μg/mL Compound: 2	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 8882434]
B16-F10	IC₅₀	54.79 μM Compound: 6	Cytotoxicity against mouse B16F10 cells after 72 hrs by alamar blue assay Cytotoxicity against mouse B16F10 cells after 72 hrs by alamar blue assay	[PMID: 24969014]
HaCaT	CC₅₀	108.6 μM Compound: 1	Cytotoxicity against human HaCaT cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HaCaT cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 33236902]
HEK293	IC₅₀	357 nM Compound: 1b	Inhibition of mouse 11beta-HSD1 expressed in HEK293 cell microsomes assessed as inhibition of [3H]cortisone conversion to [3H]cortisol by scintillation proximity assay Inhibition of mouse 11beta-HSD1 expressed in HEK293 cell microsomes assessed as inhibition of [3H]cortisone conversion to [3H]cortisol by scintillation proximity assay	[PMID: 23747808]
HeLa	GI₅₀	> 9.92 μM Compound: 1	Growth inhibition against human HeLa cells after 72 hrs by inverted microscopy Growth inhibition against human HeLa cells after 72 hrs by inverted microscopy	[PMID: 23353738]
HepG2	CC₅₀	192.4 μM Compound: 1	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 23353738]
HepG2	IC₅₀	50.72 μM Compound: 6	Cytotoxicity against human HepG2 cells after 72 hrs by alamar blue assay Cytotoxicity against human HepG2 cells after 72 hrs by alamar blue assay	[PMID: 24969014]
HL-60	IC₅₀	44.11 μM Compound: 6	Cytotoxicity against human HL60 cells after 72 hrs by alamar blue assay Cytotoxicity against human HL60 cells after 72 hrs by alamar blue assay	[PMID: 24969014]
HT-29	GI₅₀	> 9.92 μM Compound: 1	Growth inhibition against human HT-29 cells after 72 hrs by inverted microscopy Growth inhibition against human HT-29 cells after 72 hrs by inverted microscopy	[PMID: 23353738]
HT-29	ED₅₀	31.39 μg/mL Compound: 2	Cytotoxicity against human HT29 cells after 7 days by MTT assay Cytotoxicity against human HT29 cells after 7 days by MTT assay	[PMID: 8882434]
K562	GI₅₀	> 9.92 μM Compound: 1	Growth inhibition against human K562 cells after 72 hrs by inverted microscopy Growth inhibition against human K562 cells after 72 hrs by inverted microscopy	[PMID: 23353738]
K562	IC₅₀	72.53 μM Compound: 6	Cytotoxicity against human K562 cells after 72 hrs by alamar blue assay Cytotoxicity against human K562 cells after 72 hrs by alamar blue assay	[PMID: 24969014]
LLC-MK2	IC₅₀	16.5 μM Compound: 7	Antitrypanosomal activity against Trypanosoma cruzi Y amastigotes infected in monkey LLC-MK2 cells after 96 hrs by Geimsa staining method Antitrypanosomal activity against Trypanosoma cruzi Y amastigotes infected in monkey LLC-MK2 cells after 96 hrs by Geimsa staining method	[PMID: 22440015]
LLC-MK2	EC₅₀	596 μM Compound: 7	Antitrypanosomal activity against Trypanosoma cruzi Y trymastigotes infected in monkey LLC-MK2 cells after 24 hrs by Brenner counter method Antitrypanosomal activity against Trypanosoma cruzi Y trymastigotes infected in monkey LLC-MK2 cells after 24 hrs by Brenner counter method	[PMID: 22440015]
LLC-MK2	CC₅₀	76.1 μM Compound: 7	Cytotoxicity against monkey LLC-MK2 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against monkey LLC-MK2 cells after 96 hrs by sulforhodamine B assay	[PMID: 22440015]
LoVo	GI₅₀	> 9.92 μM Compound: 1	Growth inhibition against human LoVo cells after 72 hrs by inverted microscopy Growth inhibition against human LoVo cells after 72 hrs by inverted microscopy	[PMID: 23353738]
MCF7	ED₅₀	1 μg/mL Compound: 2	Cytotoxicity against human MCF7 cells after 7 days by MTT assay Cytotoxicity against human MCF7 cells after 7 days by MTT assay	[PMID: 8882434]
MIA PaCa-2	ED₅₀	22.13 μg/mL Compound: 2	Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay	[PMID: 8882434]
PANC-1	GI₅₀	> 9.92 μM Compound: 1	Growth inhibition against human PANC1 cells after 72 hrs by inverted microscopy Growth inhibition against human PANC1 cells after 72 hrs by inverted microscopy	[PMID: 23353738]
PBMC	IC₅₀	0.002 μM Compound: 15	Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced TNFalpha expression pretreated 1 hr before LPS challenge followed by incubated for 16 hrs by flow cytometry Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced TNFalpha expression pretreated 1 hr before LPS challenge followed by incubated for 16 hrs by flow cytometry	[PMID: 25338180]
PBMC	IC₅₀	0.01 μM Compound: 15	Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-1beta expression pretreated 1 hr before LPS challenge followed by incubated for 16 hrs by flow cytometry Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-1beta expression pretreated 1 hr before LPS challenge followed by incubated for 16 hrs by flow cytometry	[PMID: 25338180]
PBMC	IC₅₀	7.7 μM Compound: 15	Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-8 expression pretreated 1 hr before LPS challenge followed by incubated for 16 hrs by flow cytometry Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-8 expression pretreated 1 hr before LPS challenge followed by incubated for 16 hrs by flow cytometry	[PMID: 25338180]
PBMC	IC₅₀	80.77 μM Compound: 6	Cytotoxicity against concanavalin-A stimulated human PBMC after 72 hrs by alamar blue assay Cytotoxicity against concanavalin-A stimulated human PBMC after 72 hrs by alamar blue assay	[PMID: 24969014]
PC-3	ED₅₀	15.19 μg/mL Compound: 2	Cytotoxicity against human PC3 cells after 7 days by MTT assay Cytotoxicity against human PC3 cells after 7 days by MTT assay	[PMID: 8882434]
RAW264.7	IC₅₀	> 100 μM Compound: 1	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 20116261]
RAW264.7	IC₅₀	> 25 μM Compound: 1	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide release pretreated for 15 mins before LPS challenge measured after 24 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide release pretreated for 15 mins before LPS challenge measured after 24 hrs by Griess method	[PMID: 21334121]
SH-SY5Y	CC₅₀	45.4 μM Compound: 1	Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 33236902]

In Vitro

Kaurenoic acid (10-100 μM, 60 min) concentration-dependently inhibits the contraction of endothelial-intact or -stripped rat aortic rings induced by adrenaline and KCl^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Kaurenoic acid (1-10 mg/kg, i.g., single dose) reduces peritonitis and pain induced by lipopolysaccharides (HY-D1056) in mice^[2].
Kaurenoic acid (as a diterpene compound) is the main active ingredient in the root bark extract of A. senegalensis that exhibits anticonvulsant effects in mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mice induced by LPS^[2]
Dosage:	1, 3, 10 mg/kg; single dose
Administration:	i.g.
Result:	Inhibited LPS-induced mechanical and thermal hyperalgesia, suppressed MPO activity, regulated the redox state of mouse paws, inhibited the production of pro-inflammatory/pain cytokines (such as TNF-α, IL-1β, and IL-33), and enhanced the production of anti-inflammatory/analgesic cytokine IL-10.

Molecular Weight

302.45

Formula

C₂₀H₃₀O₂

CAS No.

6730-83-2

Appearance

Solid

Color

White to off-white

SMILES

C[C@@]1(C(O)=O)CCC[C@@]2(C)[C@@]3([H])[C@@]4(CC([C@H](CC3)C4)=C)CC[C@]12[H]

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

-20°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (330.63 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.3063 mL	16.5317 mL	33.0633 mL
5 mM	0.6613 mL	3.3063 mL	6.6127 mL
10 mM	0.3306 mL	1.6532 mL	3.3063 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.27 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (8.27 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.56%

Select Batch:

Data Sheet (280 KB) SDS (393 KB)

COA (257 KB) HNMR (288 KB) LCMS (258 KB)

Handling Instructions (2659 KB)

References

[1]. Carlos R Tirapelli, et al. Analysis of the mechanisms underlying the vasorelaxant action of kaurenoic acid in the isolated rat aorta. Eur J Pharmacol. 2004 May 25;492(2-3):233-41. [Content Brief]

[2]. Sergio M Borghi, et al. The diterpene from Sphagneticola trilobata (L.) Pruski, kaurenoic acid, reduces lipopolysaccharide-induced peritonitis and pain in mice. J Ethnopharmacol. 2021 Jun 12:273:113980. [Content Brief]

[3]. Theophine C Okoye, et al. Anticonvulsant effect of kaurenoic acid isolated from the root bark of Annona senegalensis. Pharmacol Biochem Behav. 2013 Aug:109:38-43. [Content Brief]

[4]. Mizokami SS, et al. Kaurenoic acid from Sphagneticola trilobata Inhibits Inflammatory Pain: effect on cytokine production and activation of the NO-cyclic GMP-protein kinase G-ATP-sensitive potassium channel signaling pathway. J Nat Prod. 2012 May 25;75(5):896-904. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.3063 mL	16.5317 mL	33.0633 mL	82.6583 mL
	5 mM	0.6613 mL	3.3063 mL	6.6127 mL	16.5317 mL
	10 mM	0.3306 mL	1.6532 mL	3.3063 mL	8.2658 mL
	15 mM	0.2204 mL	1.1021 mL	2.2042 mL	5.5106 mL
	20 mM	0.1653 mL	0.8266 mL	1.6532 mL	4.1329 mL
	25 mM	0.1323 mL	0.6613 mL	1.3225 mL	3.3063 mL
	30 mM	0.1102 mL	0.5511 mL	1.1021 mL	2.7553 mL
	40 mM	0.0827 mL	0.4133 mL	0.8266 mL	2.0665 mL
	50 mM	0.0661 mL	0.3306 mL	0.6613 mL	1.6532 mL
	60 mM	0.0551 mL	0.2755 mL	0.5511 mL	1.3776 mL
	80 mM	0.0413 mL	0.2066 mL	0.4133 mL	1.0332 mL
	100 mM	0.0331 mL	0.1653 mL	0.3306 mL	0.8266 mL

Kaurenoic acid Related Classifications

Neurological Disease Inflammation/Immunology Infection

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Kaurenoic acid6730-83-2Potassium ChannelBacterialKcsAAntibacterialanti-inflammatoryanticonvulsantanalgesicaortic vasorelaxantInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Kaurenoic acid

Customer Review

Other Forms of Kaurenoic acid:

Kaurenoic acid Related Antibodies

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

Kaurenoic acid Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Kaurenoic acid Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report